General information about positive NIPT results: Trisomy 7

My patient's NIPT is positive for trisomy 7. What does this mean?

Your patient's noninvasive prenatal testing (NIPT) result suggests the presence of an extra copy of chromosome 7. NIPT is a screening test; false positives can occur. The actual chance for the pregnancy to have trisomy 7 depends on many factors, including the patient's clinical and family history.

Next steps to consider: You should discuss the results and the potential clinical implications with your patient. Globally, professional medical societies recommend that all women with a positive screening result should have genetic counseling and a comprehensive ultrasound evaluation with an opportunity for diagnostic testing to confirm the results. ^{1,2} Confirmation prior to birth can also help with pregnancy and neonatal management.

See below for more information about trisomy 7.

What is trisomy 7?

Trisomy 7 is a condition that is caused by an extra chromosome number 7 (three copies instead of two).

What are the features of trisomy 7?

Most pregnancies with trisomy 7 will miscarry spontaneously. Full trisomy 7 has never been reported in a live birth. If a developing fetus has mosaic trisomy 7 (where some cells are normal and some cells have trisomy 7), there is an increased chance for the pregnancy to progress and possibly survive to term. However, liveborn infants with mosaic trisomy 7 are expected to have serious medical problems. Key features include skin pigmentary disorders, body asymmetry, renal malformations, facial dysmorphism, and growth retardation. In reported cases of prenatally diagnosed mosaic trisomy 7, the outcomes have ranged from normal to live births with clinical sequelae. The variability in clinical presentation is believed to be due to confined placental mosaicism (CPM; when trisomic cells are present in the placenta, but not in the fetus) or the degree of fetal mosaicism.

What is the prevalence of this condition?

Unknown, but very rare. For this reason, positive predictive value (PPV) cannot be calculated.

What testing could be considered?

Specialized genetic tests such as karyotyping, fluorescence *in situ* hybridization (FISH), quantitative polymerase chain reaction (qPCR), and microarray are available to confirm the presence of trisomy 7. Uniparental disomy (UPD) analysis is performed by specialized testing, such as SNP microarray, methylation testing, and short tandem repeat (STR) marker testing.

These confirmatory tests are generally performed on cells from chorionic villus sampling (CVS) or amniocentesis during pregnancy, on cord blood or peripheral blood sample after the baby is born, or on products of conception (POC) in the case of a miscarriage. The type of

invasive procedure and diagnostic testing should take into account the underlying chromosome anomaly.^{3,4}

Ultrasound evaluation may be useful in aiding with a prenatal diagnosis of trisomy 7, but a normal ultrasound cannot exclude this condition.

Special considerations

Chromosome 7 is an imprinted chromosome and UPD for chromosome 7 has specific consequences. Maternal UPD 7 leads to Silver-Russell syndrome (SRS), characterized by pre- and postnatal growth retardation, relative macrocephaly, micrognathia, triangular facies, and developmental delay. Paternal UPD 7 is clinically unapparent. There may be an increased risk for certain recessive conditions if UPD is present.⁵

The American College of Medical Genetics and Genomics (ACMG) states that specialized UPD testing should be considered for patients when there is discordance noted between the NIPT result and diagnostic testing.³

Resources for trisomy 7

MedlinePlus Genetics medlineplus.gov/genetics/chromosome/7

Unique, The Rare Chromosome Disorder Support Group rarechromo.org

References

- Rose NC, Kaimal AJ, Dugoff L, et al. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet Gynecol. 2020;136(4):e48-e69.
- Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2015;35(8):725-734.
- Cherry AM, Akkari YM, Barr KM, et al. Diagnostic cytogenetic testing following positive noninvasive prenatal screening results: a clinical laboratory practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2017;19(8):845-850.
- Van Opstal D, Srebniak MI. Cytogenetic confirmation of a positive NIPT result: evidencebased choice between chorionic villus sampling and amniocentesis depending on chromosome aberration. Expert Rev Mol Diagn. 2016;16(5):513-520.
- Del Gaudio D, Shinawi M, Astbury C, et al. Diagnostic testing for uniparental disomy: a points to consider statement from the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(7):1133-1141.

Additional resources

Chen CP, Su YN, Chern SR, et al. Mosaic trisomy 7 at amniocentesis: prenatal diagnosis and molecular genetic analyses. *Taiwan J Obstet Gynecol*. 2010;49(3):333-340.

Di Lernia V. Patterned hypopigmentation associated with prenatally diagnosed trisomy 7 mosaicism: long-term follow-up. *J Dtsch Dermatol Ges.* 2015;13(9):914-916.

Gardner RJM, Amor DJ. Gardner and Sutherland's Chromosome Abnormalities and Genetic Counseling. 5th ed. Oxford University Press; 2018..

Kalousek DK, Langlois S, Robinson WP, et al. Trisomy 7 CVS mosaicism: pregnancy outcome, placental and DNA analysis in 14 cases. *Am J Med Genet*. 1996;65(4):348-352.

Kivirikko S, Salonen R, Salo A, von Koskull H. Prenatally detected trisomy 7 mosaicism in a dysmorphic child. *Prenat Diagn*. 2002;22(7):541-544.

Kotzot D, Balmer D, Baumer A, et al. Maternal uniparental disomy 7--review and further delineation of the phenotype. *Eur J Pediatr*. 2000;159(4):247-256.

Malvestiti F, Agrati C, Grimi B, et al. Interpreting mosaicism in chorionic villi: results of a monocentric series of 1001 mosaics in chorionic villi with follow-up amniocentesis. *Prenat Diagn*. 2015;35(11):1117-1127.

Qi Y, Yang J, Hou Y, et al. The significance of trisomy 7 mosaicism in noninvasive prenatal screening. $Hum\ Genomics.\ 2019;13(1):18.$

This content is intended for healthcare professional audiences only. The information provided in this sheet is based on a literature search updated in November 2020. This Information Sheet is intended to provide some general overview of the key issues relating to its subject matter. This sheet is not intended to be an exhaustive discussion of the subject covered by the sheet nor should it be used to substitute for the exercise of a Clinical Laboratory or a Healthcare Provider's legal or professional duties relative to interpreting the test results to which this Information Sheet relates. This sheet is also not intended to serve as a recommendation of management. This sheet is not intended to be a substitute for genetic counseling. Pub. No. 1576-2020-014 QB9482